These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 90473)

  • 41. Correlation between serogroup, in vitro biofilm formation and elaboration of virulence factors by uropathogenic Pseudomonas aeruginosa.
    Mittal R; Sharma S; Chhibber S; Aggarwal S; Gupta V; Harjai K
    FEMS Immunol Med Microbiol; 2010 Mar; 58(2):237-43. PubMed ID: 19930457
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Monoclonal antibodies as probes to examine serotype-specific and cross-reactive epitopes of lipopolysaccharides from serotypes O2, O5, and O16 of Pseudomonas aeruginosa.
    Lam JS; Handelsman MY; Chivers TR; MacDonald LA
    J Bacteriol; 1992 Apr; 174(7):2178-84. PubMed ID: 1372599
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Characterisation of mouse monoclonal antibodies produced by immunisation with a single serotype component of a polyvalent Pseudomonas aeruginosa vaccine.
    Barclay GR; Yap PL; McClelland DB; Jones RJ; Roe EA; McCann MC; Micklem LR; James K
    J Med Microbiol; 1986 Feb; 21(1):87-90. PubMed ID: 3081727
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Construction and characterization of a live, attenuated aroA deletion mutant of Pseudomonas aeruginosa as a candidate intranasal vaccine.
    Priebe GP; Brinig MM; Hatano K; Grout M; Coleman FT; Pier GB; Goldberg JB
    Infect Immun; 2002 Mar; 70(3):1507-17. PubMed ID: 11854239
    [TBL] [Abstract][Full Text] [Related]  

  • 45. X-ray Irradiated Vaccine Confers protection against Pneumonia caused by Pseudomonas aeruginosa.
    Li Y; Wang Z; Liu X; Tang J; Peng B; Wei Y
    Sci Rep; 2016 Feb; 6():18823. PubMed ID: 26879055
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of the Chinese schema and the International Antigenic Typing System for serotyping Pseudomonas aeruginosa.
    Liu PV
    J Clin Microbiol; 1987 May; 25(5):824-6. PubMed ID: 3108310
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A new polyvalent Pseudomonas vaccine.
    Miler JM; Spilsbury JF; Jones RJ; Roe EA; Lowbury EJ
    J Med Microbiol; 1977 Feb; 10(1):19-27. PubMed ID: 402473
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Principle of constructing polyvalent Pseudomonas aeruginosa vaccines].
    Akatova NS
    Zh Mikrobiol Epidemiol Immunobiol; 1979 Feb; (2):56-60. PubMed ID: 84457
    [TBL] [Abstract][Full Text] [Related]  

  • 49. R-form lipopolysaccharides (LPS) of Gram-negative bacteria as possible vaccine antigens.
    Stanislavsky ES; Makarenko TA; Kholodkova EV; Lugowski C
    FEMS Immunol Med Microbiol; 1997 Jul; 18(3):139-45. PubMed ID: 9271164
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [An O-antigen study of Pseudomonas aeruginosa from serological group O11].
    Bekina KE; Ivanova NI
    Zh Mikrobiol Epidemiol Immunobiol; 1990 Jun; (6):18-20. PubMed ID: 1699370
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Determination of the O-serovars of Pseudomonas aeruginosa by slide coagglutination.
    Ansorg R; Knoche M
    Eur J Clin Microbiol; 1984 Jun; 3(3):190-4. PubMed ID: 6205872
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Vaccines against Pseudomonas aeruginosa infection: 1. Experimental studies.
    Stanislavsky ES; Joo I; Mashilova GM; Boolk VF; Boltutsy LG; Zakgeim DA; Severtśova MK; Yedvabnaya LS; Gladus MA; Fatkhinurova TI
    Vaccine; 1985 Jun; 3(2):128-36. PubMed ID: 3929491
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Cell-free Pseudomonas vaccine. II. Isolation and immunological properties of protective antigens of Pseudomonas aeruginosa].
    Stanislavskiĭ ES; Palkina NA; Bulk VF; Zhvanetskaia MI; Chekan LV
    Zh Mikrobiol Epidemiol Immunobiol; 1981; (8):37-40. PubMed ID: 6797158
    [No Abstract]   [Full Text] [Related]  

  • 54. [Cell-free Pseudomonas vaccine. III. Immunochemical analysis of purified Pseudomonas aeruginosa protein antigens and protective properties of antisera against these antigens].
    Chekan LV; Stanislavskiĭ ES; Polkina NA
    Zh Mikrobiol Epidemiol Immunobiol; 1983 Feb; (2):92-6. PubMed ID: 6188300
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy of a
    Moustafa DA; DiGiandomenico A; Raghuram V; Schulman M; Scarff JM; Davis MR; Varga JJ; Dean CR; Goldberg JB
    Infect Immun; 2023 Dec; 91(12):e0024723. PubMed ID: 37991349
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Outer membrane protein F preparation of Pseudomonas aeruginosa as a vaccine against chronic pulmonary infection with heterologous immunotype strains in a rat model.
    Gilleland HE; Gilleland LB; Matthews-Greer JM
    Infect Immun; 1988 May; 56(5):1017-22. PubMed ID: 2833440
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Experimentally determined safety and immunological activity of vaccine based on antigens isolated from Pseudomonas aeruginosa in medium K-4].
    Nuriddinova NR; Sheremet'ev NN; Ivanova LE; Garib FIu; Iskhakova KhI
    Zh Mikrobiol Epidemiol Immunobiol; 2005; (3):57-60. PubMed ID: 16028515
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Smooth lipopolysaccharide is the major protective antigen for mice in the surface extract from IATS serotype 6 contributing to the polyvalent Pseudomonas aeruginosa vaccine PEV.
    MacIntyre S; Lucken R; Owen P
    Infect Immun; 1986 Apr; 52(1):76-84. PubMed ID: 3082762
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Three new major somatic antigens of Pseudomonas aeruginosa.
    Liu PV; Wang S
    J Clin Microbiol; 1990 May; 28(5):922-5. PubMed ID: 2112563
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Motility, virulence, and protection with a flagella vaccine against Pseudomonas aeruginosa infection.
    Montie TC; Drake D; Sellin H; Slater O; Edmonds S
    Antibiot Chemother (1971); 1987; 39():233-48. PubMed ID: 3118785
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.